ArticleACS omega2026
Benchmarking the Ligand-HER2 Interactions Using Machine Learning and Molecular Dynamics Simulations.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the inhibitor-HER2 interaction mechanism remains a critical challenge in combating breast cancer. In the present work, the role of five critical residues that are deeply located in the HER2 active site was recognized. To win the race against time in learning the activities of the HER2 tyrosine kinase protein, we employed a stepwise computational procedure including a machine learning predictive regression model, atomistic molecular dynamics (MD) simulations, and the umbrella sampling MD method. A systematic mining of a data set of 8 million chemical compounds allowed us to finally identify 13 candidates whose capacities as anti-HER2 have not been reported before. Based on the computed results, a benchmark for the strength of the ligand-HER2 interaction has been established. Although van der Waals potential energy tends to stabilize ligand-protein associations, the ligand that electrostatically interacts with five residues, Lys753, Leu796, Thr798, Asp863, and Asp880, is a key factor in deciding the inhibitor strength. Significantly, the strong binding of compound lig233 was exemplified by its ability to form hydrogen bonds with Asp863 and Asp880 and maintain exceptionally short distances to many key residues, indicating the formation of strong chemical bonds. Lig233 also exhibits a binding free energy of -47 kcal/mol, two times as large as that of -21 kcal/mol for the known drug lapatinib. The fresh understanding achieved in the present study can lead to the necessary adjustments in the experimental development of HER2 inhibitors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.